Serum uric acid levels and the risk of Parkinson disease

Lau, Lonneke M. L. de; Koudstaal, Peter J.; Hofman, Albert; Breteler, Monique M.B.

doi:10.1002/ana.20663

Cited by 286 publications

(205 citation statements)

References 19 publications

Supporting

Mentioning

188

Contrasting

Unclassified

Order By: Relevance

“…The inverse association was stronger in non-smokers than smokers [659].The Rotterdam study also found lower PD risk with increasing baseline serum uric acid (p for trend 0.04), but no interaction by smoking status or gender [660]. Similarly, a case-control study nested within the Health Professionals Follow-up Study of men reported an inverse association between baseline serum uric acid and PD (RR 0.43, 95% CI 0.18-1.02 for highest versus lowest quartile of serum uric acid, p for trend 0.017) [661].…”

Section: Uric Acid and Goutmentioning

confidence: 77%

Epidemiology and etiology of Parkinson’s disease: a review of the evidence

et al. 2011

View full text Add to dashboard Cite

show abstract

Section: Uric Acid and Goutmentioning

confidence: 77%

Epidemiology and etiology of Parkinson’s disease: a review of the evidence

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Studies have evaluated a potential association between serum UA and the risk of developing Parkinson's disease, finding a lower risk among individuals with higher levels of serum UA. 31,32 Significant associations were detected between variations in SLC2A9 and memory performance. It was observed that higher UA levels might be associated with increased performance on memory-related tasks.…”

Section: Discussionmentioning

confidence: 97%

Novel allelic variants and evidence for a prevalent mutation in URAT1 causing renal hypouricemia: biochemical, genetics and functional analysis

et al. 2013

View full text Add to dashboard Cite

Renal hypouricemia (RHUC) is a heterogeneous inherited disorder characterized by impaired tubular uric acid (UA) transport with severe complications, such as acute kidney injury (AKI). Type 1 is caused by a loss-of-function mutation in the SLC22A12 gene (URAT1), type 2 in the SLC2A9 gene (GLUT9). This article describes three Czech families with RHUC type 1. The serum UA in the probands was 0.9, 1.1 and 0.5 mg/dl and expressed as an increase in the fractional excretion of UA (48, 43 and 39%). The sequencing analysis of SLC22A12 revealed three novel variants: p.G366R, p.T467M and a deletion p.L415_G417del. A detailed metabolic investigation in proband C for progressive visual failure supported suspicion of neuronal ceroid lipofuscinosis type 7 conditioned by the mutation in the MFSD8 gene. Functional studies showed significantly decreased urate uptake and a mis-localized URAT1 signal in p.G366R, p.L415_G417del and p.T467M. Furthermore, colocalization studies showed accumulation of URAT1 protein in the endoplasmic reticulum. The findings suggest that loss-of-function mutations cause RHUC via loss of UA absorption partly by protein misfolding. However, they do not necessarily lead to AKI and a possible genotype-phenotype correlation was not proposed. Furthermore, results confirm an uneven geographical and ethnic distribution of SLC22A12 variants; the p.L415_G417del mutation predominates in the Roma ethnic group in the Czech Republic.

show abstract

“…Based on a prospective population study, higher levels of serum UA were also associated with a decreased risk of PD (Chen, Mosley, Alonso, & Huang, 2009; de Lau, Koudstaal, Hofman, & Breteler, 2005). Low serum UA levels have been associated with an increased risk for developing PD, but it is unclear whether the UA levels are generally low among individuals who are prone to PD or whether the UA levels decrease during the long preclinical stages of PD (Annanmaki, Pohja, Parviainen, Hakkinen, & Murros, 2011).…”

Section: Discussionmentioning

confidence: 99%

Serum uric acid levels in Parkinson's disease and related disorders

et al. 2016

View full text Add to dashboard Cite

ObjectiveSerum uric acid (UA) levels are reported to be decreased in patients with Parkinson's disease (PD) and multiple system atrophy (MSA). However, clinical correlates of serum UA levels are still unclear in PD‐related disorders. We conducted a cross‐sectional study to evaluate the associations between serum UA levels and disease duration, disease severity, and motor function among PD, MSA, and progressive supranuclear palsy (PSP) patients.MethodsA total of 100 patients with PD, 42 patients with MSA, 30 patients with PSP, and 100 controls were included in this study. Serum UA levels were determined, and associations among serum UA levels and disease duration, disease severity, and motor function in PD, PSP, and MSA patients were evaluated.ResultsSerum UA levels were significantly lower in male PD, MSA, and PSP patients compared with the controls, but not in female patients. Serum UA levels were negatively correlated with disease duration and severity in MSA and PSP patients, but no correlations were observed in PD patients. The serum UA levels were significantly decreased in the tauopathy group (PSP patients) compared with the synucleinopathy group (PD and MSA patients) after adjusting for age, gender, and body mass index.ConclusionWe found decreased serum UA levels in male patients with PD‐related disorders (PD, MSA, and PSP) compared with male controls, and significant correlations between serum UA levels and disease severity in MSA and PSP patients.

show abstract

Serum uric acid levels and the risk of Parkinson disease

Cited by 286 publications

References 19 publications

Epidemiology and etiology of Parkinson’s disease: a review of the evidence

Epidemiology and etiology of Parkinson’s disease: a review of the evidence

Novel allelic variants and evidence for a prevalent mutation in URAT1 causing renal hypouricemia: biochemical, genetics and functional analysis

Serum uric acid levels in Parkinson's disease and related disorders

Contact Info

Product

Resources

About